{"entity":{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","aka":[],"tldr":"MRD-negative complete remission means not just no leukaemia visible under the microscope, but none detectable with tests a thousand times more sensitive. It is the goal of modern leukaemia treatment.","summary":"Complete remission with undetectable measurable residual disease by flow (10^-4) or molecular methods (10^-5 to 10^-6). Prognostic across AML, ALL, CLL, and myeloma; accepted as a regulatory endpoint in ALL (blinatumomab MRD+ label) and, since FDA ODAC 2024, as an accelerated-approval endpoint in myeloma. Drives transplant decisions (AML), blinatumomab consolidation (ALL), and duration debates (CLL).","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Minimal_residual_disease","links":[{"label":"Heuser et al., 2021 update on MRD in acute myeloid leukaemia: ELN MRD Working Party consensus (Blood 2021)","url":"https://doi.org/10.1182/blood.2021013626"}],"tags":[],"related":[],"cancers":["aml","all-leukemia","cll","multiple-myeloma"],"sections":[],"technologies":["flow-cytometry-mrd","ngs-mrd-clonoseq","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-heuser-blood"],"journals":[],"dependsOn":[],"notes":[],"category":"Endpoints"},"route":"/terms/mrd-negative-cr/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/"},{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"paper":[{"id":"paper-heuser-blood","kind":"paper","name":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","route":"/key-papers/paper-heuser-blood/"},{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/"},{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/"},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/"},{"id":"paper-viale-a-venetoclax-azacitidine-nejm-2020","kind":"paper","name":"VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy","route":"/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/"}],"target":[{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/"}],"trial":[{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/"},{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/"},{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/"},{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/"},{"id":"myelomatch","kind":"trial","name":"myeloMATCH","route":"/trials/myelomatch/"},{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/"}],"idea":[{"id":"idea-mrd-guided-transplant-aml","kind":"idea","name":"MRD-guided transplant decisions in intermediate-risk AML","route":"/ideas/idea-mrd-guided-transplant-aml/"},{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/"},{"id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/"}],"bottleneck":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"}],"drug":[{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/"}]}}